RDHL

Opaganib (ABC294640, Yeliva®)

COVID-19

Stage (next event)

Expected Date

Phase 2/3 (Preliminary Data)

Q4 2020

Catalyst Info & Data Links

TITLE: Opaganib (ABC294640, Yeliva®) in COVID - Phase 2/3 (Preliminary Data)

  • ClinicalTrial.gov (NCT04467840): Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia


WHAT IS THE CATALYST EVENT?

  • 1. Phase 2/3 Preliminary Data

  • 2. Emergency Use Application


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • Opaganib (Yeliva®, ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities. Opaganib is an investigational drug targeting several potential oncology, inflammatory and gastrointestinal indications (Learn more).

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

AMP Makes Trades in Hypo Fund

RedHill BioPharma: A Highly De-risked and Undervalued Biopharma Company with a Deep Pipeline

AMP Makes Three Trades in its Hypothetical Fund

AMP Starts a Position in Redhill Biopharma

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon